Bladder Cancer

Antisense Growth Factor Therapy Inhibits Metastatic Tumor Growth

Published in Gene Therapy Weekly, January 18th, 2001

Antisense basic fibroblast growth factor (bFGF) gene therapy via adenoviral vector works on several levels in treatment of transitional cell carcinoma of the bladder, a study conducted in mice demonstrates.

K. Inoue and colleagues at the University of Texas M.D. Anderson Cancer Center reported that in vitro, adenoviral-mediated antisense bFGF (Ad bFGF-AS) promotes endothelial cell apoptosis and inhibits reproduction of these cells. Their current experiment tested Ad bFGF-AS therapy in vivo in athymic nude mice. Transitional cell carcinoma (TCC) cell line 253J-BVR was implanted under the skin of the mice.

Inoue et al. reported their findings in the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2001-01-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry